RecruitingPhase 1NCT07348237

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-2828 in Participants With Renal Impairment


Sponsor

Merck Sharp & Dohme LLC

Enrollment

24 participants

Start Date

Mar 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.


Eligibility

Min Age: 24 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is checking how an investigational drug called MK-2828 behaves in people with severe kidney problems or who are on dialysis, compared to people with normal kidney function. When the kidneys aren't working properly, it can change how drugs are processed in the body, so researchers need to understand if dose adjustments are needed. **You may be eligible if...** - You have severe kidney disease (eGFR less than 30 mL/min) but are NOT on dialysis, OR - You have end-stage renal disease and are on regular outpatient hemodialysis (kidney dialysis) for at least 3 months - You are in generally good health apart from your kidney condition **You may NOT be eligible if...** - You have other significant illnesses that could affect how the drug is studied (for kidney disease participants) - You are healthy but have a history of significant heart, liver, kidney, blood, or neurological conditions (for healthy matched control participants) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMK-2828

Oral administration


Locations(3)

Panax Clinical Research ( Site 0003)

Miami Lakes, Florida, United States

Floridian Clinical Research ( Site 0001)

Miami Lakes, Florida, United States

Orlando Clinical Research Center ( Site 0002)

Orlando, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07348237


Related Trials